Henrietta Lacks
In reviewHenrietta Lacks built, with her own body, the most famous human cell line in history: the cervical cancer cells taken from her tumor in 1951 became “HeLa,” the first immortal human cell line and a workhorse of twentieth‑ and twenty‑first‑century biomedicine. Her cells helped make vaccines, cancer treatments and basic discoveries in genetics and virology possible, even as the woman herself lived and died largely unrecognized, a Black patient in a segregated hospital whose tissue was taken and shared without her informed consent. Born Loretta Pleasant in Roanoke, Virginia, in 1920, raised on a tobacco farm in Clover, Virginia, and later a mother of five in Baltimore, Henrietta Lacks’s life anchors the story of how Black communities have been both foundational to and exploited by American medical science. The archive distinguishes clearly between that scientific legacy—HeLa cells and what they enabled—and the biography of the person, whose dignity and authorship extend far beyond the lab bench.
1.Life and family
Henrietta Lacks was born Loretta Pleasant on August 1, 1920, in Roanoke, Virginia, to Eliza and John Pleasant, descendants of freed Black people rebuilding life in the Jim Crow South. After her mother died in 1924, she was sent to live with her grandfather, Tommy Lacks, on a tobacco farm in Clover, Halifax County, Virginia, where she grew up working the land and attending the local Black community church and gatherings. Sometime in her youth her given name shifted from Loretta to Henrietta—a change family members recalled but that the documentary record does not fully explain, a reminder of how everyday Black naming practices often went unrecorded.
In 1941 she married David “Day” Lacks, her cousin, and soon afterward they joined the wartime migration of Southern Black families to Northern cities, moving to Turner Station, a Black community outside Baltimore, Maryland. There they raised five children—Lawrence, Lucille (later called Elsie), David Jr. (Sonny), Deborah and Joseph (later Zakariyya)—while Day worked in the Bethlehem Steel mills and Henrietta built a life of work, church, cooking and care that relatives remembered as warm, stylish and socially rooted. Her daughter Elsie, who had developmental disabilities, was institutionalized at the Crownsville State Hospital, a state facility where Black patients were segregated and poorly treated; her story forms a parallel thread of medical neglect in the family’s history.
Her everyday authorship—holding a household together in a segregated industrial town, maintaining ties back to Virginia kin, raising children under racist labor and housing regimes—is the part of the story least preserved in official archives. It survives largely in family testimony recorded in Rebecca Skloot’s reporting and in oral histories held at institutions like the Schomburg Center and local Baltimore Black history projects, which the archive treats as primary evidence under its Presumption III.
2.Illness, treatment and unconsented extraction
In early 1951, shortly after the birth of her youngest child, Henrietta began to feel what she described as a “knot” in her womb and experienced abnormal bleeding, pain and discomfort, symptoms that Black women in her community often endured in silence out of fear of hospitals and cost. On January 29, 1951, she went to Johns Hopkins Hospital, one of the few institutions in Baltimore that treated Black patients, though only on a segregated public ward where Black women were clustered in separate rooms and routinely used as teaching and research material.
Doctors found a large, unusually aggressive tumor on her cervix and diagnosed her with stage I (later reclassified as stage IIB) cervical carcinoma; the tumor was described in notes as unlike others her physician had seen, glistening and purple, a detail that later loomed large in Skloot’s reconstruction of events. As part of her treatment, surgeons performed a biopsy, taking two small tissue samples—one from the tumor and one from healthy cervical tissue—and sent them without discussion or separate consent to the laboratory of Dr. George Otto Gey, a white cancer researcher at Johns Hopkins who had been trying for years to grow human cells that could survive indefinitely in culture.
At the time, Johns Hopkins, like most American hospitals, did not seek informed consent for using discarded tissue for research; the doctrine of patient autonomy that would later be central to medical ethics had not yet been codified, and poor, Black patients were particularly exposed to unconsented experimentation under the cover of free charity care. The medical record has no evidence that Henrietta was told her cells were being taken for research or that they might become a permanent line used around the world; her family and Skloot’s interviews consistently testify that she was never informed of the research use of her tissue, a silence that the archive reads as structural rather than incidental.
Henrietta underwent a series of radiation treatments, including radium insertions, over the next months, commuting between Turner Station and Johns Hopkins while still caring for her children and maintaining her household. Her pain increased, and the cancer metastasized throughout her pelvis and abdomen. On October 4, 1951, at age 31, she died in the segregated ward at Johns Hopkins and was buried in an unmarked grave near her family’s burial ground in Clover, Virginia, where later efforts by her relatives and researchers placed a headstone recognizing her as “The Mother of Modern Medicine.”
3.HeLa cells and what they built in science
In George Gey’s lab, the sample from Henrietta’s tumor did what no human cells had yet done: they attached to the glass, thrived in culture medium and divided rapidly without senescing, becoming the first successfully maintained immortal human cell line. Gey labelled them “HeLa,” using the first two letters of her first and last names, and began distributing them freely to colleagues across the country and abroad, shipping vials to anyone who asked as part of a culture of open scientific exchange that nonetheless treated the cells as depersonalised lab tools, not as extensions of a Black woman’s body and story.
HeLa cells proved extraordinarily hardy and adaptable. They were used by Jonas Salk and others to test the safety and efficacy of the polio vaccine on a massive scale, providing a standardized human cell substrate that allowed rapid, inexpensive screening and helped usher in the eradication of polio in many parts of the world. They became central to studies of cancer biology, toxicology and radiation damage, enabling researchers to understand how cells respond to carcinogens and therapies, and they were used to develop drugs for leukemia and other cancers.
Over the decades, HeLa cells played roles in mapping the human genome, developing in vitro fertilization techniques, studying the effects of gravity and spaceflight on human tissues (including experiments in orbit), and researching viruses such as HIV, human papillomavirus (HPV) and, more recently, coronaviruses. The United Nations, when honoring Henrietta Lacks in 2021, explicitly linked her cells to breakthroughs including HPV vaccines, HIV treatments, polio vaccines, and COVID‑19 research, crediting her unwitting contribution with saving “countless lives” and underpinning “many fields, including cancer, immunology and infectious disease.”
The archive reads this catalogue of achievements as Black authorship in science: the experimental systems that rebuilt human health were literally grown from Henrietta Lacks’s cells. While the formal publications bear the names of white and institutionally positioned investigators, the material basis of their discoveries—the immortal line that made their experiments possible—was created from a Black woman’s tissue taken in a segregated ward.
4.Ethics, racism and the separation of person and cell line
The scientific legacy of HeLa is distinct from Henrietta Lacks’s biography. The cells are a tool used by thousands of scientists worldwide; the person was a mother, wife, churchgoer and worker who never consented to become a global research subject. This separation became a central theme in Rebecca Skloot’s 2010 book, *The Immortal Life of Henrietta Lacks*, which braided Lacks family testimony, medical archives and Black community histories to show how a woman’s life had been overshadowed by the cell line derived from her tumor.
For decades after 1951, HeLa cells were sold and resold by commercial suppliers for profit, and used in countless experiments, while Henrietta’s name remained mostly unknown outside specialized circles. In the 1970s, scientists studying HeLa’s genetics contacted her children to obtain blood samples without fully explaining the purpose, subjecting them again to confusing and unconsented research contact. The Lacks family struggled with the realization that companies were making millions of dollars selling their mother’s cells while they themselves remained poor, uninsured or under‑insured, and largely excluded from the benefits of the science she had enabled.
The archive situates this exploitation within a broader pattern: Black patients in segregated or under‑resourced hospitals were disproportionately used as research material without transparent consent, as seen in the Tuskegee syphilis study, involuntary sterilizations and other abuses. Johns Hopkins has acknowledged that Henrietta’s cells were taken without informed consent but maintains that at the time there was no legal requirement to obtain permission for research use of discarded tissue; this is precisely the kind of “standard practice” that the archive reads as a racialized disability, excusing disregard for Black autonomy under the guise of medical routine.
HeLa cells also produced ethical dilemmas around privacy and genetic data. When the full HeLa genome was sequenced and published in 2013, it revealed information not solely about the cell line but about the inherited genetics of her descendants, raising questions about who owns and controls such data. After objections from the family and advocates, agreements were reached giving Lacks’s descendants a voice in how HeLa genomic data would be accessed and used, marking a shift toward community engagement and consent—even though the original extraction could never be undone.
5.Recognition, family claims and changing research standards
Beginning in the late twentieth century and accelerating after Skloot’s book, Henrietta Lacks has increasingly been publicly honored. Johns Hopkins established the annual Henrietta Lacks Memorial Lecture and scholarship programs, and the University of Virginia and other institutions have named plaques, statues and educational programs after her, presenting her as a “heroine of modern medicine.” In 2021, the World Health Organization and the United Nations held ceremonies recognizing her contribution and calling for equity in medical research, explicitly framing her story as emblematic of “racially unjust medical systems” and the need for consent in all use of human biological specimens.
At the same time, her family has asserted legal and moral claims. In October 2021, the estate of Henrietta Lacks filed a lawsuit against Thermo Fisher Scientific, a major biotechnology company, alleging that it knowingly profited from HeLa cells taken from her body without her consent and demanding disgorgement of profits obtained from commercializing the line. The complaint framed the case in terms of racial exploitation, arguing that white doctors at Johns Hopkins had disproportionately extracted samples from poor Black women for research and that ongoing commercialization constituted continuing unjust enrichment.
On August 1, 2023, the date that would have been Henrietta’s 103rd birthday, lawyers for the Lacks estate announced that Thermo Fisher had reached a confidential settlement with the family after a day of negotiations in federal court in Baltimore. While the terms are sealed, the existence of the settlement itself marks a recognition, in the language of corporate liability, that profiting from materials derived from unconsented, racially biased medical practices carries ongoing ethical weight. It does not retroactively establish consent, but it does shift the ground on which institutions approach legacy cases like HeLa.
The broader field of research ethics has also moved. Debates around HeLa have informed revisions to the U.S. Common Rule governing research on human subjects and have fueled calls, including in major journals like *Nature*, for consent to be required even when samples are “deidentified,” and for community partnership in decisions about tissue use. Public narratives about Henrietta Lacks now often emphasize that she unknowingly contributed to advances that saved lives around the world, while also insisting that future science must be built on transparent, respectful collaboration with patients and communities, not on secrecy and coercion.
The archive reads these developments as partial repair. They do not erase the decades in which the woman was forgotten while her cells were commodified, but they do mark a shift from erasure toward honoring her as an author of medical progress and as a Black matriarch whose story changed the rules of science.
6.Distinguishing biography from scientific legacy
Throughout this record, the archive holds a firm distinction: Henrietta Lacks’s biography is her own—the daughter of Eliza and John Pleasant, raised on a Virginia tobacco farm, a wife to Day Lacks, a mother of five, a Black woman navigating segregated hospitals and industrial Baltimore. The HeLa cell line is a scientific object derived from her tumor under conditions of unconsented extraction, later shaped by laboratory technique, global distribution networks and corporate commercialization.
To collapse the two—to speak only of “HeLa” and not of Henrietta—is to repeat the original erasure that treated her body and tissue as raw material rather than authored contribution. To attribute all scientific achievements made with HeLa cells solely to her would likewise be inaccurate; the archive credits her with providing the indispensable cellular infrastructure that made those achievements possible, while recognizing the experimental and analytic work done by named investigators. The person and the cell line are linked but not identical.
By holding this distinction, the archive can honor Henrietta Lacks as a builder of modern medicine—through the unprecedented properties of her cancer cells—while also insisting on her full humanity beyond the petri dish. Her record stands as a reminder that Black lives have been central to scientific progress, and that the future of research must be designed so that such contributions are made knowingly, consensually and with shared benefit.
The archive holds Henrietta Lacks as a central author of modern biomedical possibility: without the cells grown from her body, much of late‑twentieth‑century medical research would have been slower, smaller or impossible. She stands as both a heroine of science and a witness to how Black life was routinely treated as raw material, not partner, in the research enterprise. Her stature lies not only in what HeLa cells did in laboratories but in how her story forced medicine, law and ethics to confront informed consent, genetic ownership and racial exploitation. The archive reads the global recognition of her name, the UN honors, and the family’s legal and moral claims as overdue acknowledgments of an authorship long obscured by race and class. Henrietta Lacks’s record belongs in Science & Invention because it is a story about how Black life built the infrastructure of modern medicine—and about the refusal to let that contribution be remembered only as a case of harm rather than a foundation of human healing.
The family archive is admissible here. Photographs, letters, deeds, church programs, funeral bulletins, business records, recordings — the things that were kept when no institution was keeping them. A keeper reviews everything before it is admitted, and your name stays on it.